Given that PON1 activity is typically reduced in chronic liver diseases, including MASLD, it has been demonstrated that this reduction is associated with changes in HDL particles, the expression of peroxisome proliferator-activated receptor PPAR δ, and the regulation of monocyte chemoattractant protein-1 (MCP-1) transformation. The gene discussed is CCL2; the disease is metabolic dysfunction-associated steatotic liver disease.